About us

Nogo Receptor  

The reported prevalence of Spinal Cord Injury in the US is approximately 265,000 chronically injured individuals, and the annual incidence of new cases is 12,000. Recovery of function can be extremely limited after injury. At Axerion, we are working to develop treatments to restore function after neurological injury. Read more about our approach to treating Spinal Cord Injury.  

Cellular Prion Protein

Alzheimer's disease (AD) is the most common cause of age-related dementia, affecting more than 25 million people worldwide. We have identified a protein, cellular Prion Protein (PrP-c), as a high-affinity receptor for amyloid beta (Aβ) oligomers and mediator of Aβ’s toxic effects in the brain. We are developing molecules that inhibit Aβ oligomer binding to PrP-c as therapeutics to slow or arrest the progression of AD. Read more about our approach to treating Alzheimer’s disease.